

Nutritional prevention of cognitive decline and dementia

Ligia J. Dominguez, Mario Barbagallo

Geriatric Unit, Dept. of Internal Medicine and Geriatrics, University of Palermo, Palermo, Italy

Summary. Cognitive impairment results from a complex interplay of many factors. The most important independent predictor of cognitive decline is age but other contributing factors include demographic, genetic, socio-economic, and environmental parameters, including nutrition. The number of persons with cognitive decline and dementia will increase in the next decades in parallel with aging of the world population. Effective pharmaceutical treatments for age-related cognitive decline are lacking, emphasizing the importance of prevention strategies. There is extensive evidence supporting a relationship between diet and cognitive functions. Thus, nutritional approaches to prevent or slow cognitive decline could have a remarkable public health impact. Several dietary components and supplements have been examined in relation to their association with the development of cognitive decline. A number of studies have examined the role of dietary patterns on late-life cognition, with accumulating evidence that combinations of foods and nutrients may act synergistically to provide stronger benefit than those conferred by individual dietary components. Higher adherence to the Mediterranean dietary pattern has been associated with decreased cognitive decline and incident AD. Another dietary pattern with neuroprotective actions is the Dietary Approach to Stop Hypertension (DASH). The combination of these two dietary patterns has been associated with slower rates of cognitive decline and significant reduction in incident AD. This review evaluates the evidence for the effects of some dietary components, supplements, and dietary patterns as neuroprotective, with potential to delay cognitive decline and the onset of dementia. (www.actabiomedica.it)

Key words: Alzheimer, cognitive decline, aging, diet, nutrition, inflammation, oxidative stress

Introduction

Aging of the world population is an undeniable contemporary reality. The recently published World Report on Aging and Health (1) asserts that, for the first time in the history of mankind, most people around the world can expect to live over 60 years. Bio-demographic data suggest that half of the children alive in 2010 in countries with the highest life expectancies may reach the age of 100 years (2). The dark side of this successful story is that the number of persons with cognitive decline will increase exponentially in the coming decades (3, 4) in parallel with aging of the world population. This implies remarkable finance and human burden because dementia is one of the greatest

causes of disability (4). Worldwide, 47 million persons are currently affected by dementia with about 8 million newly diagnosed cases annually. Most of them, 60-75%, have Alzheimer's disease (AD), followed by vascular and Lewy bodies dementia (3, 4). Even if the general care of people with dementia has improved, the availability of effective interventions to significantly modify the disease is still lacking (5). Even if cognitive decline occur generally in old age, the causal brain pathology develops years before, which gives room to preventive strategies. Not only preventing, but even delaying the onset of dementia, would have profound effects on public health. Nevertheless, a very recent systematic review of 51 trials with low-moderate risk of bias concluded that the available evidence does not

support the use of pharmacological treatments (i.e., dementia medications, antihypertensive and diabetes drugs, anti-inflammatory medications, and estrogen/progestin agents) for the prevention of cognitive decline in persons with normal cognition or with mild cognitive impairment (MCI) (6). Two systematic reviews, one on cognitive training including 11 trials (7), and another on exercise including 16 trials (8), concluded that evidence for prevention of cognitive decline or dementia with these strategies is insufficient. Interestingly, a multidomain intervention including physical activity, diet, and cognitive training improved several cognitive outcomes (9).

The impact of diet and nutrition on age-associated cognitive decline is becoming a growing field as a potential modifiable contributor (10). Various minerals, micronutrients, vitamins with antioxidant/anti-inflammatory properties have been studied (11). Dietary essential fatty acids forming neuronal membranes with antioxidant, anti-excitotoxic, and anti-inflammatory actions have been tested as well (12, 13). Similar studies suggest biological plausibility and cognitive effects of other single or multi-ingredient supplements, which recently has been judged as insufficient (14). In addition, diverse dietary patterns have been studied in relation to their association with cognitive functions alluding that the benefit of nutritional factors may derive from synergistic interactions of different components contained in a food pattern (15).

In this article, we review possible mechanisms and evidence for the actions of dietary components, supplements, and dietary patterns on cognitive decline and dementia.

Possible mechanisms mediating the effects of diet on cognitive decline and AD

Overweight and obesity in adulthood and late-onset cognitive decline

Traditional risk factors for cardiovascular disease (CVD) and type 2 diabetes (T2D), both in isolation and combined, are also risk factors for the development of cognitive decline and AD (16). The clustering of risk factors (i.e., central obesity, hyperglycemia, hy-

pertension, atherogenic dyslipidemia, and a prothrombotic state), or metabolic syndrome, is directly related to the accumulation of visceral adiposity in midlife linked to overeating and sedentarism with deleterious consequences in late-life (17). Obesity has become an epidemic at all ages. In the current industrial era, there is extensive accessibility to abundant inexpensive calorie-rich food, which together with a sedentary lifestyle has paradoxically contributed to the increased life expectancy in the last century. Overeating and sedentarism have led to chronic non-communicable diseases (18), which develop easily but are very challenging to treat and may become unsustainable. A systematic review of 28 longitudinal studies conducted from 2003 to 2013 with follow-up of 5–40 years showed an increased risk of late-onset dementia in overweight and obese participants in midlife (up to 2.44 fold risk) (19). The mechanism behind this association is not yet clarified, but several possible mediators have been suggested. Overweight and obesity-related vascular consequences, i.e., hypertension, atherogenic dyslipidemia, and/or diabetes, are also risk factors for dementia (16). Yet, most analyses in the studies take into account these potential confounder. High levels of plasma amyloid proteins have been found in obese persons (20). A longitudinal study showed that being overweight or obese in midlife was associated with lower blood brain barrier (BBB) integrity almost 25 years later (21).

The accumulation and activation of macrophages in outsized adipose tissue may trigger systemic and neuroinflammation. Immune cells in adipose tissue can secrete pro-inflammatory [e.g., tumor necrosis factor (TNF), interleukin (IL)-1b, IL-6] and anti-inflammatory cytokines (adiponectin and IL-10), which maintain low-grade chronic inflammation (22). Obesity has been also linked to a switch from M2 macrophages to the proinflammatory M1 phenotype (23).

Dietary fats, specially saturated fatty acids (SFA), induce inflammatory responses on microglia, with local cytokine production, i.e., hypothalamic nuclear factor kappa B (NF- κ B), which may lead to apoptosis of neurons involved in body weight control, central regulation of energy balance, blood pressure, and glucose homeostasis (24). Obesity may also induce modifications in the developing brain of children and adolescents (25), with long-term negative consequences.

Conversely, low-calorie diets, weight reduction or frequent consumption of food rich in antioxidant/anti-inflammatory properties, or food patterns with combinations of them, have been associated with reduced markers of systemic and adipose tissue inflammation (26). Diet studies in humans have shown a link between insulin resistance and cognition (27), as well as T2D glucose regulation abnormalities and cognitive function (28). Diet interventions that improved insulin resistance have been associated with decreased inflammatory cytokines and improved cognition (29, 30).

Oxidative stress and chronic metabolic inflammation

A pro-oxidant, pro-inflammatory state is characteristic of aging and age-related degenerative diseases resulting in harmful damage on cellular components. The brain is particularly susceptible to oxidative damage. Cerebral metabolism needs large amounts of energy, and it is dependent on aerobic conditions; it is also rich in polyunsaturated fatty acids (PUFAs), which are oxidizable, and in transition metals, which facilitate free radicals generation. Moreover, the brain has low levels of antioxidant systems compared to other body structures. This might render brain tissue prone to damage due to accumulation of neurotoxic peptides such as amyloid-beta (31). Autoptic studies have shown increased protein oxidative damage, lipid peroxidation, glycol-oxidation, and reduced antioxidant enzyme systems in brain tissue from AD patients (32).

Increasing evidence suggests neuroinflammation as the origin of AD. Aggregated and misfolded proteins (e.g., amyloid) bind to microglia toll-like receptors (TLRs) and CD4, initiating innate immune responses with production of inflammatory mediators (33). Microglia surrounding amyloid plaques and tangles were already described by Alois Alzheimer, but only in recent times the role of microglia inflammation has been studied. Neuroinflammation is a key protective mechanism; yet, when uncontrolled and chronic, it may become harmful by the incessant release of free radicals, proteolytic enzymes, nitric oxide, complementary factors, cytokines, or excitatory amino acids (34). Amyloid-beta accretion induces neuroinflamma-

tion, which consecutively produces more amyloid-beta, propagating the injury (35). Increased neuroinflammation has been shown in MCI and AD patients vs. healthy controls using positron emission tomography and imaging with radioligand C-11-DAA1106 (36). Amyloid-beta may lead to a preponderance of M1 cells vs. M2 (anti-inflammatory cells) and loss of the ability to switch phenotypes and lessen destruction (34). Nitric oxide (NO) in excess may induce inflammatory signals, identified as key players in neurodegenerative diseases with consequent neuronal death (37).

Autophagy and prothrombotic state

Autophagy mediates degradation and recycling and of cellular proteins, whose efficiency declines with age. It involves clearance of misfolded proteins and aggregates such as amyloid, which is altered in AD (38). There is evidence that the mammalian target of rapamycin (mTOR) signaling, a key player of cellular senescence, affects glucose metabolism, energy production, mitochondrial function, and autophagy in the brain. These events are central in age-associated cognitive decline and AD (39).

Other features of AD are vascular disorders (e.g., decreased cerebral blood flow, BBB disruption, and cerebrovascular dysfunction) and a prothrombotic state (e.g., clot formation, activated platelets, decreased fibrinolysis). Fibrinogen accumulates with amyloid-beta, which promotes amyloid beta fibrillization and generation of fibrin resistant to degradation. A recent study showed higher platelet activating factor acetylhydrolase activity and higher oxidized-LDL levels when compared AD patients with control subjects (40).

Dietary components and supplements with suggested effects on cognitive decline and AD

Omega-3 fatty acids

The PUFAs are essential constituents of neuronal cell membranes, preserving membrane fluidity for neurotransmitter communication and synaptic vesicle fusion. They may be precursors for lipid messengers in

signaling processes to promote neuroprotection or neuronal damage (41). There is evidence of PUFAs deficit in the hippocampus, cortex, and cerebellum in the aged brain, which may be worse in AD (42). The most widely studied PUFAs regarding cognitive decline are omega-3 PUFAs with dissimilar results. A systematic review reported data supporting a role for long-chain omega-3 PUFAs in the reduction of cognitive decline in persons without dementia (43). Nevertheless, other trials have shown negative results. The "Supplementation with Folate, vitamin B6 and B12 and/or Omega-3 fatty acids" trial including 1,748 participants with a history of CVD reported no significant effects of vitamin B and omega-3 fatty acid supplementation on cognitive function (44). A double-blind RCT involving 302 cognitively intact persons aged ≥ 65 years assigned to 1,8 g/day eicosapentaenoic (EPA)-docosahexaenoic (DHA), 0.4 g/day EPA-DHA, or placebo for a short period (26 weeks) found no significant effects (45). A meta-analysis of results from 3,536 persons aged >60 years without cognitive dysfunction at baseline supplemented with omega-3 PUFAs reported no significant effects on cognitive function (46). An epidemiological study of Chinese adults showed that persons aged ≥ 65 years who consumed ≥ 100 g/week of fish had a reduction of about 65% in the mean annual rate of global cognitive decline with no associations among adults aged 55-64 years (47). Recently, the "Multidomain Alzheimer Preventive Trial" reported that multidomain intervention and omega-3 PUFAs supplementation, either alone or in combination, had no significant effects on cognitive decline over 3 years in 1525 participants (48).

Curcuminoids

Curcumin is a polyphenolic compound from the rhizome of *Curcuma longa* contained in curry spice turmeric, considered an effective therapy for several conditions in traditional Indian medicine, widely used in that population, and a potent antioxidant (49). In 2000, a study by Ganguli et al. (50) reported a lower prevalence of AD in the Indian population compared to the US population. Ng et al. found that older healthy people who consume more frequently curry had better cognitive performance (51). Numerous experimental studies confirmed the potent anti-oxidant and anti-in-

flammatory properties of curcumin and its protection on AD animal models. Three RCTs have been so far completed. Baum et al. (52) enrolled 34 patients with AD receiving either 1 or 4 g/day of curcumin or placebo for 6 months and reported no significant effects in Mini Mental State Examination (MMSE). Ringman et al. (53), randomized 36 patients with dementia to 2 or 4 g/day of Curcumin C3 Complex (95% of curcuminoids) or placebo for 24 weeks, extended to 48 weeks as an open-label trial with Curcumin C3 Complex for the placebo arm. The authors did not observe any significant difference between treatment groups and placebo in any of the scores (ADAS-Cog, NPI, ADCS-ADL, MMSE) or cerebrospinal fluid markers. Hishikawa et al. (54) showed that 3 dementia patients treated with 100 mg/day of curcumin and donepezil had a lower NPI score after 12 weeks of therapy. Supplements of curcumin have limited bioavailability, which has been suggested to improve with lipidated formulations (55).

Magnesium

Compelling evidence shows that magnesium (Mg) deficiency results in increased free radicals production in various tissues, increased oxidative tissue damage, increased superoxide anion production by inflammatory cells, decreased antioxidant enzyme expression and activity, decreased cellular and tissue antioxidant levels, and increased oxygen peroxide production (56, 57); Mg is essential for synaptic conduction, affects N-methyl-D-aspartate (NMDA) receptor response to excitatory amino acids (58), inhibits calcium channels, calcium influx, and glutamate release, and has effects on stability and viscosity of cell membranes (56). Mg insufficiency produces vasospasm while elevated Mg induces tone relaxation in cerebral arteries (59). Due to the above mentioned reasons, the role of Mg in cognitive decline and dementia has been examined in recent years. Former studies showed low serum Mg levels (60) and autaptic brain tissue concentrations in AD patients (61). We observed reduced ionized free Mg concentrations in plasma obtained from AD patients (62), which were related to cognitive dysfunction severity. Cilliler et al. (63) reported negative associations of serum Mg levels and 2 rating AD severity scales (Global Deterioration Scale and Clinical Dementia

Rating), further confirming a potential protective role of Mg on cognitive function. There are no specific trials with Mg supplements in the prevention or therapy of cognitive disorders; hence, whether Mg supplementation may exert protective effects against AD remains to be further elucidated in well-design trials.

Cocoa and cocoa-derived products

Cocoa is a rich source of flavonoids, which has shown cardiovascular benefits. Some small acute and short-term chronic trials have suggested neuroprotective properties. A study in 18 persons aged 50–65 years reported significant increases in regional perfusion across the brain following consumption of the high flavanol drink (494 mg), particularly in the anterior cingulate cortex and the central opercular cortex of the parietal lobe measured with spin labelling functional MRI (64). A small study of 34 healthy persons (mean age 72 ± 6 years) showed an increased blood flow velocity in the middle cerebral artery after one (8%) and two weeks (10%) of flavanol-rich cocoa consumption using transcranial Doppler ultrasound (65). In an RCT, healthy persons aged 50–69 years who consumed a high cocoa flavanol-containing diet for 3 months exhibited enhanced dentate gyrus function, as measured by functional MRI and by cognitive testing (66). A prospective study involving 531 participants aged ≥ 65 years followed for median 48 months showed that chocolate intake was associated with a 41% lower risk of cognitive decline after adjustment for confounders (67).

The mechanisms proposed to explain the potential benefit of cocoa and derived products are: 1) direct interactions with cellular signaling that promote neurogenesis, neuronal function and brain connectivity, and 2) blood-flow improvement and angiogenesis in the brain and sensory systems. The preliminary evidence shown above underscores the need for further well-design and large RCT on these interesting compounds.

Tea and (-)-Epigallocatechin-3-gallate (EGCG)

Tea is traditionally indicated as a cognitive stimulator in Asian cultures. This effect has been confirmed in some studies and has been linked to antioxidants contained in tea, such as EGCG, L-theanine, and caf-

feine (68). Tea may also exert neuroprotective actions by regulation of stress hormones and inhibition of acetylcholinesterase (69). However, there is currently inconsistent evidence with no definitive conclusion on its neuroprotective actions (70). Bioactive compounds, such as L-theanine and EGCG, may have some potential due to their anti-amyloidogenic and antioxidant properties in vitro, but the evidence for their use as nutraceuticals is limited and there is no recommendation currently for their use in clinical practice.

Caffeine

There is evidence of antioxidant (71) and amyloid-beta suppressive properties of caffeine in animal models of AD (72). The reduction in amyloid-plaques is associated with a stimulation of protein kinase A activity, increased phosphor-CREB levels, and reduced phosphor-JNK and phosphor-ERK expression in mouse models of AD, promoting survival cascades in the brain (72, 73). It is well-known that coffee and caffeine strengthen short-term memory and cognition, but there is limited evidence suggesting long-term effects. A case-control study of 124 older persons with MCI showed that high serum levels of caffeine were associated with lack of progression to dementia (74). Another study reported that consumption of 3–5 cups of coffee per day reduced incident AD and dementia by 65% (75). Among 3494 men from the Honolulu-Asia Aging Study, deceased men in the highest quartile of caffeine intake were less likely to have any neuropathological dementia lesion vs. men in the lowest quartile. Yet, coffee and caffeine intake in midlife were not associated with risk of cognitive impairment, overall dementia, AD, vascular dementia, or moderate/high levels of neuropathological lesions (76).

A meta-analysis of studies exploring the relationship of caffeine consumption and cognitive decline reported nonsignificant effects (77), but few and largely heterogeneous studies were included. A Portuguese study reported an association of caffeine consumption with slower cognitive decline (78), while a study from France found no association (79). A longitudinal study reported less cognitive decline among coffee consumers but no dose response (80). Another showed no relationship (81). There is no evidence from RCTs.

Phytoestrogen compounds

Studies on soy isoflavones usually include mixtures of them, such as genistein and daidzein, which impede to discriminate the effects of specific components on cognition. Studies of soy consumption and phytoestrogen supplements on cognitive function have reported variable and inconclusive results (82), with overall absence of adverse events (83). An initial positive cognitive effect in adult age appears to reverse in older women; in men the data are even more equivocal (82). Discrepancies may be explained by the use of different isoflavone supplements at variable doses in small short-term trials. Studies showing no effect of phytoestrogens on cognition are mostly from European cohorts, with low dietary soy consumption. Studies of older Asian populations with higher consumption of soy-derived foods show lower rates of cognitive decline. After oral intake of conjugated isoflavones, daidzein is converted to S-equol by a gut biotransformation. About 70% of older Japanese persons are “equol producers” (84), which may help explain the different results in Asian vs. Europeans studies.

In the Women’s Isoflavone Soy Health (WISH) trial, 313 postmenopausal women aged 45-92 years were randomized to receive 25 g/d of isoflavone-rich soy protein (containing genistein, daidzein, and glycitein) or milk protein-matched placebo. Cognitive function was assessed at baseline and after 2.5 years. There were no differences between the groups in cognition change from baseline. Nevertheless, women within 5-10 years of menopause in the isoflavone group showed a nonsignificant ($p=0.07$) trend toward cognitive improvement, and a significant improvement in verbal episodic memory. Consistent producers of urinary S-equol showed a nonsignificant ($p=0.08$) trend toward cognitive improvement (85). Further studies are necessary to validate these findings. There are no RCTs of phytoestrogens for the prevention or treatment of AD.

Resveratrol

This hydroxyphenol is a polyphenol contained in berries. Most dietary resveratrol in humans comes from grapes and red wine (86). Biological properties of

resveratrol include antioxidant and anti-inflammatory actions (87). Studies in animal models of AD have shown reduced hippocampal neurodegeneration and increased memory performance, but human clinical trials of resveratrol on cognition are limited. A placebo-control study in 22 healthy adults showed a dose-dependent (250-500 mg/day) increase in cerebral blood flow in the prefrontal cortex during cognitive tasks (88). Another small study including 23 overweight persons, aged 50-75 years, receiving resveratrol (200 mg/d) for 26 weeks vs. a group receiving placebo, reported improved memory performance and higher functional connectivity of the hippocampus in neuroimaging with resveratrol treatment (89). There are several ongoing clinical trials on resveratrol investigating its potential effects on cognitive function, MCI and AD (90). At present, there is no data on toxicity of chronic resveratrol supplementation. There is no sufficiently substantiated evidence for prescribing this supplement to improve cognitive function.

Gingko biloba

An RCT included 3,069 participants randomized into *Gingko biloba* treatment or placebo to determine whether *G. biloba* supplementation could prevent dementia among older adults who were cognitively intact or had mild cognitive impairment at baseline. Participants were followed for a median of 6.1 years, and study results indicated no difference in the rate of cognitive decline for the two treatment groups (91).

Garlic (Allium sativum)

Garlic extracts have shown antioxidant properties and protection against amyloid-beta-induced neurotoxic effects in experimental animals (92). Allicin, an organosulfur compound contained in garlic, inhibited cholinesterase enzymes and upregulated brain acetylcholine levels in vitro (93). Nevertheless, there are no clinical trials for these compounds. In the Doetinchem Cohort Study, including 2613 participants aged 43-70 years, higher consumption of allium (onion, garlic, and leek) was associated with worse scores on cognitive flexibility and speed of cognitive processes in cross-sectional analyses, while in longitudinal analyses, al-

lium consumption was not associated with cognitive decline (94).

Vitamins

In 4,052 participants from the Physicians' Health Study and Physicians' Health Study II, there was no significant effect on cognitive function with short-term beta-carotene (provitamin A) treatment and beneficial effect with longer-term (18-year) administration (95).

Studies on the effect of vitamin B on cognition have produced mixed results. An RCT of 299 men >75 years showed no significant effect on cognitive function of 2-year supplementation with folic acid, vitamin B6, and B12 (96). Similarly, a meta-analysis of 9 RCTs (n=2,835) indicated no significant effect of folic acid with or without other B vitamins on cognitive function (97). Conversely, an RCT of 900 persons aged 60–74 years showed that folic acid+vitamin B12 were significantly superior vs. placebo for improving cognitive tests (98).

A number of studies have examined the combined effects of vitamins C and E on cognitive function in healthy populations with conflicting results. The Women's Health Study (6,377 women over 65 years) showed no significant effect on cognitive function of vitamin E supplementation (99). Analyses of 616 over 65-years-old participants of the Duke Established Populations for Epidemiologic Studies showed that vitamins C and/or E supplements had no influence on incident dementia or AD (100). On the contrary, the Canadian Study of Health and Aging (894 participants aged ≥65 years) reported that a combination of vitamins C and E significantly decreased the rate of cognitive decline (101). A recent study analyzed the relations of alpha- and gamma-tocopherol brain concentrations with AD neuropathology among 115 deceased participants of the prospective Rush Memory and Aging Project. Gamma-tocopherol concentrations were associated with lower amyloid load and lower neurofibrillary tangle severity, while alpha-tocopherol concentrations were not associated with neuropathology (102).

The Third National Health and Nutrition Examination Survey showed an association of vitamin D deficiency with an increased risk of cognitive decline

in the US (103). However, the Women's Health Initiative showed no significant effect of vitamin D and calcium supplementation on cognitive function in 2,034 women aged over 65 years, followed for a mean of 7.8 years (104).

Results from the Age-Related Eye Disease Study including 2,166 participants followed for 6.9 years showed that a combination of antioxidant vitamins (vitamins E and C, beta-carotene), zinc, and copper had no significant effects on any of six tests of cognitive function (105). Similarly, the Women's Antioxidant Cardiovascular Study that included 2,824 women with or at risk for CVD who received a combination of vitamin E, beta-carotene, and vitamin C or placebo showed no effects on cognition with the multivitamin supplementation (106).

Dietary patterns

The incidence of chronic diseases, including dementia and AD, has been assessed in relation to dietary patterns in populations of various ethnicity, culture, or religious beliefs. There is no single dietary or lifestyle intervention proven in RCTs to prevent incident AD. Nevertheless, epidemiological data suggest that adopting a healthy, balanced diet and lifestyle known to improve cardiovascular risk may help delay incident AD (107).

Mediterranean diet (MeDiet)

The dietary pattern consumed traditionally by populations bordering the Mediterranean Sea has been extensively reported as a model of healthy eating. MeDiet characteristics are shown in Table 1. A greater adherence to MeDiet has been associated with a reduced incidence of overall mortality, cardiovascular mortality, cardiovascular events incidence, cancer mortality and/or incidence, and incident Parkinson's disease and AD (108).

A recent systematic review of longitudinal cohorts examining MeDiet effects on cognition found that participants in the highest tertile of adherence to MeDiet had 33% less risk of MCI or AD when vs. those in the lowest tertile (109). The RCT PREDIMED (Prevención con Dieta Mediterránea), includ-

Table 1. Characteristics of the Mediterranean dietary pattern.**Mediterranean dietary pattern**

- Olive oil as the main source of fat
- Fresh fruits and vegetables; legumes, nuts, seeds
- Bread and other grain products (pasta, rice from whole grains)
- Herbs and spices (providing taste and facilitating low use of added salt)
- Foods that have undergone minimal processing, that are fresh and locally produced
- Frequent consumption of fish and seafood (2-3 times per week)
- Dairy products on a daily basis, mainly yogurt (less often small portions of cheese)
- Red meat consumed in moderation, if possible as a part of stews and other recipes, not often (1-2 every month)
- Eggs (providing high quality proteins)
- Fresh fruit everyday as dessert; sweets, cakes and dairy desserts only occasionally in small amounts
- Water
- Wine in moderation, with meals
- Moderate portion size
- Moderate physical active every day
- Meals in the company of others

ing adults aged 55-80 years at high cardiovascular risk, showed that participants on a MeDiet supplemented with either EVOO or nuts, had a reduced incidence of cardiovascular events vs. participants following a low-fat diet over 5-years of follow-up (110). Two sub-analysis of this RCT have reported improved cognitive function with the MeDiet supplemented with either EVOO oil or nuts vs. low-fat diet (111, 112).

Several longitudinal studies have examined the effects of MeDiet on AD in cohorts from the US (113-117), and France (118, 119). Two reviews (108, 120) concluded that even if there is some evidence that adherence to MeDiet is associated with a reduced risk of AD, additional confirmation in populations with different ethnicities and dietary habits is necessary. The Personality and Total Health (PATH) through Life longitudinal study (121) of healthy participants from Australia found no protection of MeDiet for cognitive decline, while the Australian Imaging, Biomarkers and Lifestyle (AIBL) study (122) showed that participants with AD and MCI had lower adherence to MeDiet than healthy controls. A 7-year longitudinal study (123) evaluated adherence to HEI-2005 or to MeDiet in relation to cognitive change in 3,790 adults aged >65 years from the ongoing Chicago Health and Aging Project longitudinal study. The results showed that white participants had higher energy-adjusted MeDiet scores but lower HEI-2005 scores compared to black participants. Higher MeDiet scores, adjusted

for confounders, were associated with slower rates of cognitive decline, but no association was found for HEI-2005 scores. MeDiet encompasses other cultural and lifestyle components, such as physical activity, adequate rest, social engagement, and culinary activities (124). These lifestyle factors have shown positive effects on delaying cognitive decline. Future studies should consider all MeDiet lifestyle factors into their design.

Dietary approaches to stop hypertension (DASH)

This balanced eating plan effectively lowers cardiovascular outcomes (125). DASH characteristics are shown in Table 2. A prospective study examined the associations between DASH and MeDiet with age-related cognitive changes in 3831 participants aged >65 years, followed for >11 years. Higher adherence to DASH and MeDiet and greater consumption of whole grains, nuts and legumes were significantly associated with higher average MMSE scores (126). A combined dietary pattern of MeDiet and DASH (or MIND) in 960 participants of the Memory and Aging Project followed for a mean of 4.7 years was positively associated with slower decline in global and 5 single cognitive domains, after adjusting for confounders (127). In 923 participants, aged 58-98 years, followed for average 4.5 years, there was a significant reduction in incident AD for the second and third tertile

Table 2. Characteristics of DASH (Dietary Approaches to Stop Hypertension)**Dietary Approaches to Stop Hypertension**

- Eating vegetables, fruits, and whole grains
- Including fat-free or low-fat dairy products, fish, poultry, beans, nuts, and vegetable oils
- Limiting foods that are high in saturated fat, such as fatty meats, full-fat dairy products, and tropical oils such as coconut, palm kernel, and palm oils
- Limiting sugar-sweetened beverages and sweets

of adherence scores to MIND diet vs. the lowest tertile (128). Replications of these positive results with DASH and MIND are needed in other populations to confirm their relevance to brain health.

Other dietary patterns with no proven or conflicting effects on cognitive function or prevention of cognitive decline

Several dietary patterns with confirmed benefit for diverse health outcomes (e.g., cardiovascular health, total mortality, incident cancer, body weight control) have not definitely proven effects on the prevention of cognitive decline or dementia.

- *Healthy Eating Index-2005 (HEI-2005) (Dietary Guidelines for Americans)* - Two cross-sectional studies (129, 130) showed associations of HEI-2005 and improvements in cognition. However two longitudinal studies (123, 131) followed up to 7.6 years showed no association. A longer study (132) (11-year follow-up) showed less cognitive decline with increased HEI scores, indicating that a longer duration may be needed to disclose effects of diet on cognition.

- *Okinawa Diet* - Notwithstanding this dietary pattern is followed by populations with some of the longest life expectancies in the world, there is still no solid evidence for its effects on prevention of cognitive decline and AD. A study showed a higher incident dementia in 157 migrants from Okinawa to Brazil vs. 2,217 residents of Okinawa (133). The 9-year difference between the studies and dissimilar sample size may have affected the results.

- *Vegetarian Diets* - The incidence of dementia in those consuming vegetarian diets and meat-eating diets was compared in two cohort sub-studies of the Adventist Health Study (134). The first study showed that persons who ate meat were more than twice as likely to become demented as their vegetarian counter-

parts. A second analysis showed no significant difference in the incidence of dementia between vegetarian and meat-eating subjects, with no clear explanation for the difference between the two sub-studies. There was no clear evidence of any standardized cognitive assessment during the study.

- *Paleolithic Diet* - A study of 20 overweight postmenopausal women compared the effects of Paleolithic diet vs. Nordic Nutrition Recommendations followed for 6 months on parameters of functional MRI, episodic memory tasks, and weight loss. There was a significant improvement in episodic memory performance after both dietary interventions, which was associated with increased hippocampal activity, decreased waist circumference and reduced plasma FFA without differences between the diets (135). There are no studies on the effects of Paleolithic diet on incident AD.

- *Ketogenic Diet* - This dietary pattern has been associated with neuroprotective effects in some forms of epilepsy. While there is no current evidence of AD prevention with ketogenic diet, a small double-blind placebo-controlled study of 20 patients with MCI or AD showed memory scores improvement in patients receiving medium-chain triglycerides in non-*APOE* ϵ 4 patients but not in *APOE* ϵ 4 positive patients (136). A clinical trial of 152 participants showed similar results (137). Most findings with KD come from animal studies and a solid validation in human trials is still warranted.

- *Low-copper Diet* - A longitudinal study of 3718 participants showed that high intakes of copper, mostly supplements, together with a high-fat diet resulted in more rapid cognitive decline after 5.5 years follow-up (138). In 32 patients with mild to moderate AD, those with low plasma Cu had significantly higher ADAS-cog scores (139) Squitti et al. suggest that the

promotion of a low-Cu diet may potentially reduce the risk of AD (140). Nevertheless, there is no evidence that depletion or supplementation of Cu may modify AD incidence or pathology.

Conclusions

Results from large-scale epidemiologic studies and clinical trials generally do not demonstrate an independent role for most of the nutritional and dietary factors that have been examined for the prevention of cognitive decline or AD. Further research is needed to clarify the possible benefits of the single dietary components.

The effects of MeDiet and DASH on cardiovascular health are well established, and there is moderately convincing evidence that adherence to these dietary patterns is associated with a reduced risk of AD, especially with the combination of both dietary patterns. Further confirmation in populations with different ethnicities and different dietary behaviors is needed. There is at present no clear evidence to support effects of HEI-2005, Okinawa, vegetarian, Paleolithic, ketogenic, or low-copper diets on the prevention of cognitive decline or AD.

Studying dietary patterns may help understand possible synergistic actions of foods and nutrients combinations in order to prevent or delay the onset of cognitive decline and dementia.

References

1. Beard JR, Officer A, de Carvalho IA, Sadana R, Pot AM, Michel JP, Lloyd-Sherlock P, Epping-Jordan JE, Peeters G, Mahanani WR, Thiyagarajan JA, Chatterji S. The world report on ageing and health: A policy framework for healthy ageing. *Lancet* 2016; 387: 2145-2154
2. Vaupel JW. Biodemography of human ageing. *Nature* 2010; 464: 536-542
3. 2014 alzheimer's disease facts and figures. *Alzheimers Dement* 2014; 10: e47-92
4. Prince MJ, Wu F, Guo Y, Gutierrez Robledo LM, O'Donnell M, Sullivan R, Yusuf S. The burden of disease in older people and implications for health policy and practice. *Lancet* 2015; 385: 549-562
5. Feldman HH, Haas M, Gandy S, Schoepp DD, Cross AJ, Mayeux R, Sperling RA, Fillit H, van de Hoef DL, Dougal S, Nye JS. Alzheimer's disease research and development: A call for a new research roadmap. *Ann N Y Acad Sci* 2014; 1313: 1-16
6. Fink HA, Jutkowitz E, McCarten JR, Hemmy LS, Butler M, Davila H, Ratner E, Calvert C, Barclay TR, Brasure M, Nelson VA, Kane RL. Pharmacologic interventions to prevent cognitive decline, mild cognitive impairment, and clinical alzheimer-type dementia: A systematic review. *Ann Intern Med* 2018; 168: 39-51
7. Butler M, McCreedy E, Nelson VA, Desai P, Ratner E, Fink HA, Hemmy LS, McCarten JR, Barclay TR, Brasure M, Davila H, Kane RL. Does cognitive training prevent cognitive decline?: A systematic review. *Ann Intern Med* 2018; 168: 63-68
8. Brasure M, Desai P, Davila H, Nelson VA, Calvert C, Jutkowitz E, Butler M, Fink HA, Ratner E, Hemmy LS, McCarten JR, Barclay TR, Kane RL. Physical activity interventions in preventing cognitive decline and alzheimer-type dementia: A systematic review. *Ann Intern Med* 2018; 168: 30-38
9. Ngandu T, Lehtisalo J, Solomon A, Levalahti E, Ahtiluoto S, Antikainen R, Backman L, Hanninen T, Jula A, Laatikainen T, Lindstrom J, Mangialasche F, Paajanen T, Pajala S, Peltonen M, Rauramaa R, Stigsdotter-Neely A, Strandberg T, Tuomilehto J, Soininen H, Kivipelto M. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (finger): A randomised controlled trial. *Lancet* 2015; 385: 2255-2263
10. Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of alzheimer's disease: An analysis of population-based data. *Lancet Neurol* 2014; 13: 788-794
11. Meydani M. Antioxidants and cognitive function. *Nutr Rev* 2001; 59: S75-80; discussion S80-72
12. Farooqui AA, Ong WY, Horrocks LA, Chen P, Farooqui T. Comparison of biochemical effects of statins and fish oil in brain: The battle of the titans. *Brain Res Rev* 2007; 56: 443-471
13. Lukiw WJ, Bazan NG. Docosahexaenoic acid and the aging brain. *J Nutr* 2008; 138: 2510-2514
14. Butler M, Nelson VA, Davila H, Ratner E, Fink HA, Hemmy LS, McCarten JR, Barclay TR, Brasure M, Kane RL. Over-the-counter supplement interventions to prevent cognitive decline, mild cognitive impairment, and clinical alzheimer-type dementia: A systematic review. *Ann Intern Med* 2018; 168: 52-62
15. Jacobs DR, Jr., Orlich MJ. Diet pattern and longevity: Do simple rules suffice? A commentary. *Am J Clin Nutr* 2014; 100 Suppl 1: 313S-319S
16. de la Torre JC. Vascular risk factors: A ticking time bomb to alzheimer's disease. *Am J Alzheimers Dis Other Demen* 2013; 28: 551-559
17. Dominguez LJ, Barbagallo M. The biology of the metabolic syndrome and aging. *Curr Opin Clin Nutr Metab Care* 2016; 19: 5-11

18. Sepulveda J, Murray C. The state of global health in 2014. *Science* 2014; 345: 1275-1278
19. Emmerzaal TL, Kiliaan AJ, Gustafson DR. 2003-2013: A decade of body mass index, alzheimer's disease, and dementia. *J Alzheimers Dis* 2015; 43: 739-755
20. Jahangiri A, Wilson PG, Hou T, Brown A, King VL, Tannock LR. Serum amyloid a is found on apob-containing lipoproteins in obese humans with diabetes. *Obesity (Silver Spring)* 2013; 21: 993-996
21. Gustafson DR, Karlsson C, Skoog I, Rosengren L, Lissner L, Blennow K. Mid-life adiposity factors relate to blood-brain barrier integrity in late life. *J Intern Med* 2007; 262: 643-650
22. Grant RW, Dixit VD. Adipose tissue as an immunological organ. *Obesity (Silver Spring)* 2015; 23: 512-518
23. Harford KA, Reynolds CM, McGillicuddy FC, Roche HM. Fats, inflammation and insulin resistance: Insights to the role of macrophage and t-cell accumulation in adipose tissue. *Proc Nutr Soc* 2011; 70: 408-417
24. Velloso LA, Folli F, Saad MJ. Tlr4 at the crossroads of nutrients, gut microbiota, and metabolic inflammation. *Endocr Rev* 2015; 36: 245-271
25. Liang J, Matheson BE, Kaye WH, Boutelle KN. Neurocognitive correlates of obesity and obesity-related behaviors in children and adolescents. *Int J Obes (Lond)* 2014; 38: 494-506
26. Calder PC, Ahluwalia N, Brouns F, Buetler T, Clement K, Cunningham K, Esposito K, Jonsson LS, Kolb H, Lansink M, Marcos A, Margioris A, Matusheski N, Nordmann H, O'Brien J, Pugliese G, Rizkalla S, Schalkwijk C, Tuomilehto J, Warnberg J, Watzl B, Winklhofer-Roob BM. Dietary factors and low-grade inflammation in relation to overweight and obesity. *Br J Nutr* 2011; 106 Suppl 3: S5-78
27. Cholerton B, Baker LD, Craft S. Insulin, cognition, and dementia. *Eur J Pharmacol* 2013; 719: 170-179
28. Geijselaers SL, Sep SJ, Stehouwer CD, Biessels GJ. Glucose regulation, cognition, and brain mri in type 2 diabetes: A systematic review. *Lancet Diabetes Endocrinol* 2015; 3: 75-89
29. Kelly KR, Haus JM, Solomon TP, Patrick-Melin AJ, Cook M, Rocco M, Barkoukis H, Kirwan JP. A low-glycemic index diet and exercise intervention reduces tnf(alpha) in isolated mononuclear cells of older, obese adults. *J Nutr* 2011; 141: 1089-1094
30. Bayer-Carter JL, Green PS, Montine TJ, VanFossen B, Baker LD, Watson GS, Bonner LM, Callaghan M, Levenson JB, Walter BK, Tsai E, Plymate SR, Postupna N, Wilkinson CW, Zhang J, Lampe J, Kahn SE, Craft S. Diet intervention and cerebrospinal fluid biomarkers in amnesic mild cognitive impairment. *Arch Neurol* 2011; 68: 743-752
31. Kapogiannis D, Mattson MP. Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and alzheimer's disease. *Lancet Neurol* 2011; 10: 187-198
32. Mao P, Reddy PH. Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in alzheimer's disease: Implications for early intervention and therapeutics. *Biochim Biophys Acta* 2011; 1812: 1359-1370
33. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A, Petzold GC, Town T, Morgan D, Shinohara ML, Perry VH, Holmes C, Bazan NG, Brooks DJ, Hunot S, Joseph B, Deigendesch N, Garaschuk O, Boddeke E, Dinarello CA, Breitner JC, Cole GM, Golenbock DT, Kummer MP. Neuroinflammation in alzheimer's disease. *Lancet Neurol* 2015; 14: 388-405
34. Cherry JD, Olschowka JA, O'Banion MK. Neuroinflammation and m2 microglia: The good, the bad, and the inflamed. *J Neuroinflammation* 2014; 11: 98
35. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for alzheimer's disease: An appraisal for the development of therapeutics. *Nat Rev Drug Discov* 2011; 10: 698-712
36. Yasuno F, Ota M, Kosaka J, Ito H, Higuchi M, Doronbekov TK, Nozaki S, Fujimura Y, Koeda M, Asada T, Suhara T. Increased binding of peripheral benzodiazepine receptor in alzheimer's disease measured by positron emission tomography with [11c]daa1106. *Biol Psychiatry* 2008; 64: 835-841
37. Yuste JE, Tarragon E, Campuzano CM, Ros-Bernal F. Implications of glial nitric oxide in neurodegenerative diseases. *Front Cell Neurosci* 2015; 9: 322
38. Martinez-Vicente M. Autophagy in neurodegenerative diseases: From pathogenic dysfunction to therapeutic modulation. *Semin Cell Dev Biol* 2015; 40: 115-126
39. Perluigi M, Di Domenico F, Butterfield DA. Mtor signaling in aging and neurodegeneration: At the crossroad between metabolism dysfunction and impairment of autophagy. *Neurobiol Dis* 2015
40. Bacchetti T, Vignini A, Giulietti A, Nanetti L, Provinciali L, Luzzi S, Mazzanti L, Ferretti G. Higher levels of oxidized low density lipoproteins in alzheimer's disease patients: Roles for platelet activating factor acetyl hydrolase and paraoxonase-1. *J Alzheimers Dis* 2015
41. Bazan NG. Lipid signaling in neural plasticity, brain repair, and neuroprotection. *Mol Neurobiol* 2005; 32: 89-103
42. Liu JJ, Green P, John Mann J, Rapoport SI, Sublette ME. Pathways of polyunsaturated fatty acid utilization: Implications for brain function in neuropsychiatric health and disease. *Brain Res* 2015; 1597: 220-246
43. Fotuhi M, Mohassel P, Yaffe K. Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or alzheimer disease: A complex association. *Nat Clin Pract Neurol* 2009; 5: 140-152
44. Andreeva VA, Kesse-Guyot E, Barberger-Gateau P, Fezeu L, Hercberg S, Galan P. Cognitive function after supplementation with b vitamins and long-chain omega-3 fatty acids: Ancillary findings from the su.Fol.Om3 randomized trial. *Am J Clin Nutr* 2011; 94: 278-286
45. van de Rest O, Geleijnse JM, Kok FJ, van Staveren WA, Dullemeijer C, Oolderikert MG, Beekman AT, de Groot

- CP. Effect of fish oil on cognitive performance in older subjects: A randomized, controlled trial. *Neurology*. 2008; 71: 430-438
46. Sydenham E, Dangour AD, Lim WS. Omega 3 fatty acid for the prevention of cognitive decline and dementia. *Cochrane Database Syst Rev* 2012; 6: CD005379
47. Qin B, Plassman BL, Edwards LJ, Popkin BM, Adair LS, Mendez MA. Fish intake is associated with slower cognitive decline in chinese older adults. *J Nutr* 2014; 144: 1579-1585
48. Andrieu S, Guyonnet S, Coley N, Cantet C, Bonnefoy M, Bordes S, Bories L, Cufi MN, Dantoine T, Dartigues JF, Desclaux F, Gabelle A, Gasnier Y, Pesce A, Sudres K, Touchon J, Robert P, Rouaud O, Legrand P, Payoux P, Caubere JP, Weiner M, Carrie I, Ousset PJ, Vellas B. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (mapt): A randomised, placebo-controlled trial. *Lancet Neurol* 2017; 16: 377-389
49. Sikora E, Scapagnini G, Barbagallo M. Curcumin, inflammation, ageing and age-related diseases. *Immun Ageing* 2010; 7: 1
50. Ganguli M, Chandra V, Kamboh MI, Johnston JM, Dodge HH, Thelma BK, Juyal RC, Pandav R, Belle SH, DeKosky ST. Apolipoprotein e polymorphism and alzheimer disease: The indo-us cross-national dementia study. *Arch Neurol* 2000; 57: 824-830
51. Ng TP, Chiam PC, Lee T, Chua HC, Lim L, Kua EH. Curry consumption and cognitive function in the elderly. *Am J Epidemiol* 2006; 164: 898-906
52. Baum L, Lam CW, Cheung SK, Kwok T, Lui V, Tsoh J, Lam L, Leung V, Hui E, Ng C, Woo J, Chiu HF, Goggins WB, Zee BC, Cheng KF, Fong CY, Wong A, Mok H, Chow MS, Ho PC, Ip SP, Ho CS, Yu XW, Lai CY, Chan MH, Szeto S, Chan IH, Mok V. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with alzheimer disease. *J Clin Psychopharmacol* 2008; 28: 110-113
53. Ringman JM, Frautschy SA, Teng E, Begum AN, Bardens J, Beigi M, Gyls KH, Badmaev V, Heath DD, Apostolova LG, Porter V, Vanek Z, Marshall GA, Hellemann G, Sugar C, Masterman DL, Montine TJ, Cummings JL, Cole GM. Oral curcumin for alzheimer's disease: Tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. *Alzheimers Res Ther* 2012; 4: 43
54. Hishikawa N, Takahashi Y, Amakusa Y, Tanno Y, Tuji Y, Niwa H, Murakami N, Krishna UK. Effects of turmeric on alzheimer's disease with behavioral and psychological symptoms of dementia. *Ayu* 2012; 33: 499-504
55. Begum AN, Jones MR, Lim GP, Morihara T, Kim P, Heath DD, Rock CL, Pruitt MA, Yang F, Hudspeth B, Hu S, Faull KF, Teter B, Cole GM, Frautschy SA. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and alzheimer's disease. *J Pharmacol Exp Ther* 2008; 326: 196-208
56. Barbagallo M, Belvedere M, Dominguez LJ. Magnesium homeostasis and aging. *Magnes Res* 2009; 22: 235-246
57. Barbagallo M, Dominguez LJ. Magnesium and aging. *Curr Pharm Des* 2010; 16: 832-839
58. Choi DW. Ionic dependence of glutamate neurotoxicity. *J Neurosci* 1987; 7: 369-379
59. Altura BT, Altura BM. Withdrawal of magnesium causes vasospasm while elevated magnesium produces relaxation of tone in cerebral arteries. *Neurosci Lett* 1980; 20: 323-327
60. Lemke MR. Plasma magnesium decrease and altered calcium/magnesium ratio in severe dementia of the alzheimer type. *Biol Psychiatry* 1995; 37: 341-343
61. Durlach J. Magnesium depletion and pathogenesis of alzheimer's disease. *Magnes Res* 1990; 3: 217-218
62. Barbagallo M, Belvedere M, Di Bella G, Dominguez LJ. Altered ionized magnesium levels in mild-to-moderate alzheimer's disease. *Magnes Res* 2011; 24: S115-121
63. Cilliler AE, Ozturk S, Ozbakir S. Serum magnesium level and clinical deterioration in alzheimer's disease. *Gerontology* 2007; 53: 419-422
64. Lampion DJ, Pal D, Moutsiana C, Field DT, Williams CM, Spencer JP, Butler LT. The effect of flavanol-rich cocoa on cerebral perfusion in healthy older adults during conscious resting state: A placebo controlled, crossover, acute trial. *Psychopharmacology (Berl)* 2015; 232: 3227-3234
65. Sorond FA, Lipsitz LA, Hollenberg NK, Fisher ND. Cerebral blood flow response to flavanol-rich cocoa in healthy elderly humans. *Neuropsychiatr Dis Treat* 2008; 4: 433-440
66. Brickman AM, Khan UA, Provenzano FA, Yeung LK, Suzuki W, Schroeter H, Wall M, Sloan RP, Small SA. Enhancing dentate gyrus function with dietary flavanols improves cognition in older adults. *Nat Neurosci* 2014; 17: 1798-1803
67. Moreira A, Diogenes MJ, de Mendonca A, Lunet N, Barros H. Chocolate consumption is associated with a lower risk of cognitive decline. *J Alzheimers Dis* 2016; 53: 85-93
68. Einother SJ, Martens VE. Acute effects of tea consumption on attention and mood. *Am J Clin Nutr* 2013; 98: 1700S-1708S
69. Chen D, Milacic V, Chen MS, Wan SB, Lam WH, Huo C, Landis-Piwowar KR, Cui QC, Wali A, Chan TH, Dou QP. Tea polyphenols, their biological effects and potential molecular targets. *Histol Histopathol* 2008; 23: 487-496
70. Song J, Xu H, Liu F, Feng L. Tea and cognitive health in late life: Current evidence and future directions. *J Nutr Health Aging* 2012; 16: 31-34
71. Azam S, Hadi N, Khan NU, Hadi SM. Antioxidant and prooxidant properties of caffeine, theobromine and xanthine. *Med Sci Monit* 2003; 9: BR325-330
72. Arendash GW, Mori T, Cao C, Mamcarz M, Runfeldt M, Dickson A, Rezai-Zadeh K, Tane J, Citron BA, Lin X, Echeverria V, Potter H. Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged alzheimer's disease mice. *J Alzheimers Dis* 2009; 17: 661-680
73. Zeitlin R, Patel S, Burgess S, Arendash GW, Echeverria V. Caffeine induces beneficial changes in pka signaling and jnk and erk activities in the striatum and cortex of alzheimer's transgenic mice. *Brain Res* 2011; 1417: 127-136

74. Cao C, Loewenstein DA, Lin X, Zhang C, Wang L, Duara R, Wu Y, Giannini A, Bai G, Cai J, Greig M, Schofield E, Ashok R, Small B, Potter H, Arendash GW. High blood caffeine levels in mci linked to lack of progression to dementia. *J Alzheimers Dis* 2012; 30: 559-572
75. Eskelinen MH, Ngandu T, Tuomilehto J, Soininen H, Kivipelto M. Midlife coffee and tea drinking and the risk of late-life dementia: A population-based caide study. *J Alzheimers Dis* 2009; 16: 85-91
76. Gelber RP, Petrovitch H, Masaki KH, Ross GW, White LR. Coffee intake in midlife and risk of dementia and its neuropathologic correlates. *J Alzheimers Dis* 2011; 23: 607-615
77. Santos C, Costa J, Santos J, Vaz-Carneiro A, Lunet N. Caffeine intake and dementia: Systematic review and meta-analysis. *J Alzheimers Dis* 2010; 20 Suppl 1: S187-204
78. Santos C, Lunet N, Azevedo A, de Mendonca A, Ritchie K, Barros H. Caffeine intake is associated with a lower risk of cognitive decline: A cohort study from portugal. *J Alzheimers Dis* 2010; 20 Suppl 1: S175-185
79. Ritchie K, Carriere I, de Mendonca A, Portet F, Dartigues JF, Rouaud O, Barberger-Gateau P, Ancelin ML. The neuroprotective effects of caffeine: A prospective population study (the three city study). *Neurology* 2007; 69: 536-545
80. Arab L, Biggs ML, O'Meara ES, Longstreth WT, Crane PK, Fitzpatrick AL. Gender differences in tea, coffee, and cognitive decline in the elderly: The cardiovascular health study. *J Alzheimers Dis* 2011; 27: 553-566
81. Laitala VS, Kaprio J, Koskenvuo M, Raiha I, Rinne JO, Silventoinen K. Coffee drinking in middle age is not associated with cognitive performance in old age. *Am J Clin Nutr* 2009; 90: 640-646
82. Soni M, Rahardjo TB, Soekardi R, Sulistyowati Y, Lestariningsih, Yesufu-Udechuku A, Irsan A, Hogervorst E. Phytoestrogens and cognitive function: A review. *Maturitas* 2014; 77: 209-220
83. Alekel DL, Genschel U, Koehler KJ, Hofmann H, Van Loan MD, Beer BS, Hanson LN, Peterson CT, Kurzer MS. Soy isoflavones for reducing bone loss study: Effects of a 3-year trial on hormones, adverse events, and endometrial thickness in postmenopausal women. *Menopause* 2015; 22: 185-197
84. Jackson RL, Greiwe JS, Schwen RJ. Emerging evidence of the health benefits of s-equol, an estrogen receptor beta agonist. *Nutr Rev* 2011; 69: 432-448
85. Henderson VW, St John JA, Hodis HN, Kono N, McCleary CA, Franke AA, Mack WJ. Long-term soy isoflavone supplementation and cognition in women: A randomized, controlled trial. *Neurology* 2012; 78: 1841-1848
86. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: The in vivo evidence. *Nat Rev Drug Discov* 2006; 5: 493-506
87. Park EJ, Pezzuto JM. The pharmacology of resveratrol in animals and humans. *Biochim Biophys Acta* 2015; 1852: 1071-1113
88. Kennedy DO, Wightman EL, Reay JL, Lietz G, Okello EJ, Wilde A, Haskell CF. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: A double-blind, placebo-controlled, crossover investigation. *Am J Clin Nutr* 2010; 91: 1590-1597
89. Witte AV, Kerti L, Margulies DS, Floel A. Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. *J Neurosci* 2014; 34: 7862-7870
90. Tome-Carneiro J, Larrosa M, Gonzalez-Sarrias A, Tomas-Barberan FA, Garcia-Conesa MT, Espin JC. Resveratrol and clinical trials: The crossroad from in vitro studies to human evidence. *Curr Pharm Des* 2013; 19: 6064-6093
91. Snitz BE, O'Meara ES, Carlson MC, Arnold AM, Ives DG, Rapp SR, Saxton J, Lopez OL, Dunn LO, Sink KM, DeKosky ST. Ginkgo biloba for preventing cognitive decline in older adults: A randomized trial. *JAMA* 2009; 302: 2663-2670
92. Ray B, Chauhan NB, Lahiri DK. The "aged garlic extract" (age) and one of its active ingredients s-allyl-l-cysteine (sac) as potential preventive and therapeutic agents for alzheimer's disease (ad). *Curr Med Chem* 2011; 18: 3306-3313
93. Kumar S. Dual inhibition of acetylcholinesterase and butyrylcholinesterase enzymes by allicin. *Indian J Pharmacol* 2015; 47: 444-446
94. Nooyens AC, Bueno-de-Mesquita HB, van Boxtel MP, van Gelder BM, Verhagen H, Verschuren WM. Fruit and vegetable intake and cognitive decline in middle-aged men and women: The doetinchem cohort study. *Br J Nutr* 2011; 106: 752-761
95. Grodstein F, Kang JH, Glynn RJ, Cook NR, Gaziano JM. A randomized trial of beta carotene supplementation and cognitive function in men: The physicians' health study ii. *Arch Intern Med* 2007; 167: 2184-2190
96. Ford AH, Flicker L, Alfonso H, Thomas J, Clarnette R, Martins R, Almeida OP. Vitamins b(12), b(6), and folic acid for cognition in older men. *Neurology* 2010; 75: 1540-1547
97. Wald DS, Kasturiratne A, Simmonds M. Effect of folic acid, with or without other b vitamins, on cognitive decline: Meta-analysis of randomized trials. *Am J Med* 2010; 123: 522-527 e522
98. Walker JG, Batterham PJ, Mackinnon AJ, Jorm AF, Hickie I, Fenech M, Kljakovic M, Crisp D, Christensen H. Oral folic acid and vitamin b-12 supplementation to prevent cognitive decline in community-dwelling older adults with depressive symptoms--the beyond ageing project: A randomized controlled trial. *Am J Clin Nutr* 2012; 95: 194-203
99. Kang JH, Cook N, Manson J, Buring JE, Grodstein F. A randomized trial of vitamin e supplementation and cognitive function in women. *Arch Intern Med* 2006; 166: 2462-2468
100. Fillenbaum GG, Kuchibhatla MN, Hanlon JT, Artz MB, Pieper CF, Schmader KE, Dysken MW, Gray SL. Dementia and alzheimer's disease in community-dwelling elders taking vitamin c and/or vitamin e. *Ann Pharmacother* 2005; 39: 2009-2014

101. Maxwell CJ, Hicks MS, Hogan DB, Basran J, Eibly EM. Supplemental use of antioxidant vitamins and subsequent risk of cognitive decline and dementia. *Dement Geriatr Cogn Disord* 2005; 20: 45-51
102. Morris MC, Schneider JA, Li H, Tangney CC, Nag S, Bennett DA, Honer WG, Barnes LL. Brain tocopherols related to alzheimer's disease neuropathology in humans. *Alzheimers Dement* 2015; 11: 32-39
103. Llewellyn DJ, Lang IA, Langa KM, Melzer D. Vitamin d and cognitive impairment in the elderly u.s. Population. *J Gerontol A Biol Sci Med Sci* 2011; 66: 59-65
104. Rossom RC, Espeland MA, Manson JE, Dysken MW, Johnson KC, Lane DS, LeBlanc ES, Lederle FA, Masaki KH, Margolis KL. Calcium and vitamin d supplementation and cognitive impairment in the women's health initiative. *J Am Geriatr Soc* 2012; 60: 2197-2205
105. Yaffe K, Clemons TE, McBee WL, Lindblad AS. Impact of antioxidants, zinc, and copper on cognition in the elderly: A randomized, controlled trial. *Neurology* 2004; 63: 1705-1707
106. Kang JH, Cook NR, Manson JE, Buring JE, Albert CM, Grodstein F. Vitamin e, vitamin c, beta carotene, and cognitive function among women with or at risk of cardiovascular disease: The women's antioxidant and cardiovascular study. *Circulation* 2009; 119: 2772-2780
107. Mucke L. Neuroscience: Alzheimer's disease. *Nature* 2009; 461: 895-897
108. Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the mediterranean diet on health: An updated systematic review and meta-analysis. *Am J Clin Nutr* 2010; 92: 1189-1196
109. Singh B, Parsaik AK, Mielke MM, Erwin PJ, Knopman DS, Petersen RC, Roberts RO. Association of mediterranean diet with mild cognitive impairment and alzheimer's disease: A systematic review and meta-analysis. *J Alzheimers Dis* 2014; 39: 271-282
110. Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F, Gomez-Gracia E, Ruiz-Gutierrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pinto X, Basora J, Munoz MA, Sorli JV, Martinez JA, Martinez-Gonzalez MA. Primary prevention of cardiovascular disease with a mediterranean diet. *N Engl J Med* 2013; 368: 1279-1290
111. Valls-Pedret C, Sala-Vila A, Serra-Mir M, Corella D, de la Torre R, Martinez-Gonzalez MA, Martinez-Lapiscina EH, Fito M, Perez-Heras A, Salas-Salvado J, Estruch R, Ros E. Mediterranean diet and age-related cognitive decline: A randomized clinical trial. *JAMA Intern Med* 2015; 175: 1094-1103
112. Martinez-Lapiscina EH, Clavero P, Toledo E, Estruch R, Salas-Salvado J, San Julian B, Sanchez-Tainta A, Ros E, Valls-Pedret C, Martinez-Gonzalez MA. Mediterranean diet improves cognition: The predimed-navarra randomised trial. *J Neurol Neurosurg Psychiatry* 2013; 84: 1318-1325
113. Scarmeas N, Stern Y, Tang MX, Mayeux R, Luchsinger JA. Mediterranean diet and risk for alzheimer's disease. *Ann Neurol* 2006; 59: 912-921
114. Scarmeas N, Luchsinger JA, Mayeux R, Stern Y. Mediterranean diet and alzheimer disease mortality. *Neurology* 2007; 69: 1084-1093
115. Scarmeas N, Stern Y, Mayeux R, Manly JJ, Schupf N, Luchsinger JA. Mediterranean diet and mild cognitive impairment. *Arch Neurol* 2009; 66: 216-225
116. Scarmeas N, Luchsinger JA, Schupf N, Brickman AM, Cosentino S, Tang MX, Stern Y. Physical activity, diet, and risk of alzheimer disease. *JAMA* 2009; 302: 627-637
117. Gu Y, Luchsinger JA, Stern Y, Scarmeas N. Mediterranean diet, inflammatory and metabolic biomarkers, and risk of alzheimer's disease. *J Alzheimers Dis* 2010; 22: 483-492
118. Feart C, Samieri C, Rondeau V, Amieva H, Portet F, Dartigues JF, Scarmeas N, Barberger-Gateau P. Adherence to a mediterranean diet, cognitive decline, and risk of dementia. *JAMA* 2009; 302: 638-648
119. Feart C, Torres MJ, Samieri C, Jutand MA, Peuchant E, Simopoulos AP, Barberger-Gateau P. Adherence to a mediterranean diet and plasma fatty acids: Data from the bordeaux sample of the three-city study. *Br J Nutr* 2011; 106: 149-158
120. Solfrizzi V, Panza F, Frisardi V, Seripa D, Logroscino G, Imbimbo BP, Pilotto A. Diet and alzheimer's disease risk factors or prevention: The current evidence. *Expert Rev Neurother* 2011; 11: 677-708
121. Cherbuin N, Anstey KJ. The mediterranean diet is not related to cognitive change in a large prospective investigation: The path through life study. *Am J Geriatr Psychiatry* 2012; 20: 635-639
122. Gardener S, Gu Y, Rainey-Smith SR, Keogh JB, Clifton PM, Mathieson SL, Taddei K, Mondal A, Ward VK, Scarmeas N, Barnes M, Ellis KA, Head R, Masters CL, Ames D, Macaulay SL, Rowe CC, Szoek C, Martins RN. Adherence to a mediterranean diet and alzheimer's disease risk in an australian population. *Transl Psychiatry* 2012; 2: e164
123. Tangney CC, Kwasny MJ, Li H, Wilson RS, Evans DA, Morris MC. Adherence to a mediterranean-type dietary pattern and cognitive decline in a community population. *Am J Clin Nutr* 2011; 93: 601-607
124. Yannakoulia M, Kontogianni M, Scarmeas N. Cognitive health and mediterranean diet: Just diet or lifestyle pattern? *Ageing Res Rev* 2015; 20: 74-78
125. Tyson CC, Nwankwo C, Lin PH, Svetkey LP. The dietary approaches to stop hypertension (dash) eating pattern in special populations. *Curr Hypertens Rep* 2012; 14: 388-396
126. Wengreen H, Munger RG, Cutler A, Quach A, Bowles A, Corcoran C, Tschanz JT, Norton MC, Welsh-Bohmer KA. Prospective study of dietary approaches to stop hypertension- and mediterranean-style dietary patterns and age-related cognitive change: The cache county study on memory, health and aging. *Am J Clin Nutr* 2013; 98: 1263-1271

127. Morris MC, Tangney CC, Wang Y, Sacks FM, Barnes LL, Bennett DA, Aggarwal NT. Mind diet slows cognitive decline with aging. *Alzheimers Dement* 2015
128. Morris MC, Tangney CC, Wang Y, Sacks FM, Bennett DA, Aggarwal NT. Mind diet associated with reduced incidence of alzheimer's disease. *Alzheimers Dement* 2015
129. Huijbregts PP, Feskens EJ, Rasanen L, Fidanza F, Alberti-Fidanza A, Nissinen A, Giampaoli S, Kromhout D. Dietary patterns and cognitive function in elderly men in finland, italy and the netherlands. *Eur J Clin Nutr* 1998; 52: 826-831
130. Correa Leite ML, Nicolosi A, Cristina S, Hauser WA, Nappi G. Nutrition and cognitive deficit in the elderly: A population study. *Eur J Clin Nutr* 2001; 55: 1053-1058
131. Shatenstein B, Ferland G, Belleville S, Gray-Donald K, Kergoat MJ, Morais J, Gaudreau P, Payette H, Greenwood C. Diet quality and cognition among older adults from the nuage study. *Exp Gerontol* 2012; 47: 353-360
132. Wengreen HJ, Neilson C, Munger R, Corcoran C. Diet quality is associated with better cognitive test performance among aging men and women. *J Nutr* 2009; 139: 1944-1949
133. Yamada T, Kadekaru H, Matsumoto S, Inada H, Tanabe M, Moriguchi EH, Moriguchi Y, Ishikawa P, Ishikawa AG, Taira K, Yamori Y. Prevalence of dementia in the older japanese-brazilian population. *Psychiatry Clin Neurosci* 2002; 56: 71-75
134. Giem P, Beeson WL, Fraser GE. The incidence of dementia and intake of animal products: Preliminary findings from the adventist health study. *Neuroepidemiology* 1993; 12: 28-36
135. Boraxbekk CJ, Stomby A, Ryberg M, Lindahl B, Larsson C, Nyberg L, Olsson T. Diet-induced weight loss alters functional brain responses during an episodic memory task. *Obes Facts* 2015; 8: 261-272
136. Reger MA, Henderson ST, Hale C, Cholerton B, Baker LD, Watson GS, Hyde K, Chapman D, Craft S. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. *Neurobiol Aging* 2004; 25: 311-314
137. Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Study of the ketogenic agent ac-1202 in mild to moderate alzheimer's disease: A randomized, double-blind, placebo-controlled, multicenter trial. *Nutr Metab (Lond)* 2009; 6: 31
138. Morris MC, Evans DA, Tangney CC, Bienias JL, Schneider JA, Wilson RS, Scherr PA. Dietary copper and high saturated and trans fat intakes associated with cognitive decline. *Arch Neurol* 2006; 63: 1085-1088
139. Pajonk FG, Kessler H, Supprian T, Hamzei P, Bach D, Schweickhardt J, Herrmann W, Obeid R, Simons A, Falkai P, Multhaup G, Bayer TA. Cognitive decline correlates with low plasma concentrations of copper in patients with mild to moderate alzheimer's disease. *J Alzheimers Dis* 2005; 8: 23-27
140. Squitti R, Siotto M, Polimanti R. Low-copper diet as a preventive strategy for alzheimer's disease. *Neurobiol Aging* 2014; 35 Suppl 2: S40-50
141. Loeff M, Walach H. Copper and iron in alzheimer's disease: A systematic review and its dietary implications. *Br J Nutr* 2012; 107: 7-19

Received: 22 April 2018

Accepted: 28 April 2018

Correspondence:

Ligia J Dominguez, MD

Geriatric Unit, Dept. of Internal Medicine and Geriatrics,
University of Palermo, Palermo, Italy

Viale F. Scaduto 6/c - 90144 Palermo, Italy

Tel. 0039-91-6552885

Fax: 0039-91-6552952

E-mail: ligia.dominguez@unipa.it